Clinical Research Papers:
A three-microRNA signature for lung squamous cell carcinoma diagnosis in Chinese male patients
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1669 views | HTML 1928 views | ?
Lan Zhang1,*, Xia Shan2,*, Jun Wang3,*, Jun Zhu4, Zebo Huang1, Huo Zhang1, Xin Zhou1, Wenfang Cheng5, Yongqian Shu1, Wei Zhu1 and Ping Liu1
1Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China
2Department of Respiration, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210000, PR China
3Department of Thoracic Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China
4Department of Radiation Oncology, Jiangsu Cancer Hospital, Nanjing 210009, PR China
5Department of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, PR China
*These authors have contributed equally to this work
Wei Zhu, email: [email protected]
Ping Liu, email: [email protected]
Keywords: serum microRNA, lung SCC, diagnostic biomarker, qRT-PCR
Received: December 21, 2016 Accepted: May 16, 2017 Published: July 28, 2017
Various studies have demonstrated the diagnostic value of microRNA (miRNA) for lung cancer, but miRNA signatures varied between different subtypes. Whether serum miRNAs could be used as biomarkers in lung squamous cell carcinoma (SCC) remains unknown. Using quantitative real-time polymerase chain reaction (qRT-PCR) based Exiqon panel, 38 differentially expressed miRNAs were identified from 3 male lung SCC pool samples and 1 normal control (NC) pool in the initial screening phase. After the training (24 SCC VS. 15 NCs), testing (44 SCC VS. 57 NCs) and external validation (34 SCC VS. 36 NCs VS. 10 pulmonary hamartoma) processes via qRT-PCR, we identified a three-miRNA panel ((miR-106a-5p, miR-20a-5p and miR-93-5p) to be a potential diagnostic marker for male lung SCC patients. The areas under the receiver operating characteristic (ROC) curve of the three-miRNA panel for the training, testing and validation phases were 0.969, 0.881 and 0.954 respectively. In addition, this signature could also differentiate lung SCC from pulmonary hamartoma (AUC=0.900). The 3 miRNAs were consistently up-regulated in lung SCC tissues (23 SCC VS. 23 NCs) and serum exosomes (17 SCC VS. 24 NCs). Moreover, expression of the 3 miRNAs was decreased in arterial serum (n = 3). In conclusion, we established a three-miRNA signature in the peripheral serum with considerable clinical value in the diagnosis of male lung SCC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.